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KEY POINTS 
 Aspirin has anti-inflammatory and anti-atherosclerotic properties that could make this drug ideal 
for the treatment of depression.  
 In our study, we did not find any effect of aspirin on reducing the risk of depression in 4,000 
participants over 8 years of follow-up.  
 Future randomized controlled trials are needed.  
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ABSTRACT  
Objective: Aspirin exhibits anti-atherosclerotic and anti-inflammatory properties - two potentially 
risk factors for depression. The relationship between aspirin use and depression, however, remains 
unclear. We investigated whether the aspirin use is associated with a decreased incidence of 
depressive symptoms in a large North American cohort.  
Methods: Data from the Osteoarthritis Initiative (OAI) dataset, a multi-center, longitudinal study on 
community-dwelling adults was analyzed. Aspirin use was defined through self-report in the past 30 
days and confirmed by a trained interviewer. Incident depressive symptoms were defined as a score 
of > 16 in the 20-item Center for Epidemiologic Studies-Depression (CES-D) scale.  
Results: A total of 137 participants (mean age 65 years, 55.5% female) were using aspirin at baseline. 
Compared to 4,003 participants not taking aspirin, no differences in CES-D at baseline were evident 
(p=0.65). After a median follow-up time of 8 years, the incidence of depressive symptoms was similar 
in those taking aspirin at baseline (43; 95%CI=3-60) and in aspirin non-users (38; 95%CI=36-41) per 
1,000 years; log-rank test=0.63). Based on Cox’s regression analysis adjusted for eleven potential 
confounders, aspirin use was not significantly associated with the development of depressive 
symptoms (Hazard Ratio=1.12; 95%CI=0.78-1.62; p=0.54). Adjustment for propensity scores or the 
use of propensity score matching did not alter the results.  
Conclusion: Our study found that after adjustment for confounders, prescription of aspirin offered 
no significant protection against incident depressive symptoms. Whether aspirin is beneficial in a 
sub-group of depression with high levels of inflammation remains to be investigated in future studies. 
 
Keywords: aspirin; depression; epidemiology; cohort; survey; psychiatry 
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INTRODUCTION 
It is known that aspirin exerts effects on the inflammatory cascades, irreversibly inhibiting 
cyclooxygenase (COX)–1, and modifying enzyme activity of COX-2, suppressing production of 
prostaglandins and thromboxanes.(Vane and Botting, 2003) These anti-inflammatory and anti-
platelet mechanisms are the biological underpinning for which aspirin is used in the primary and 
secondary prevention of cardiovascular conditions.(Berger et al., 2011)  Moreover these effects have 
led to the assumption that  aspirin could have positive effects on other diseases, such as dementia 
(Nilsson et al., 2003), cancer (Rothwell et al., 2010) and mental disorders.(Berk et al., 2013; Solmi et 
al., 2015)  
 
Atherosclerosis and inflammation are two well-known risk factors for a number of psychiatric 
conditions.(Berk et al., 2013) A growing body of evidence has suggested that people who are 
depressed  have higher levels of serum inflammatory cytokines.(Miller and Raison, 2016; 
Strawbridge et al., 2015) A recent meta-analysis of 82 studies comprising 3,212 participants with 
MDD vs. 2,798 healthy controls found that people with MDD have higher peripheral levels of several 
inflammatory cytokines and chemokines.(Kohler, Cristiano; Freitas, Thiago; Maes et al., 2016) 
Similarly, depressed people are more likely to have cardiometabolic abnormalities and atherosclerotic 
lesions.(Pizzi et al., 2012; Tiemeier et al., 2004) Recent meta-analyses have suggested that 
medications with an anti-inflammatory effect such as statins(Salagre et al., 2016) and 
celecoxib(Köhler et al., 2014) may improve depressive symptoms. Aspirin may also improve 
atherosclerotic lesions and decrease inflammatory parameters, thus preventing the onset of 
depression.  
 
The literature regarding the possible impact of aspirin on depression is limited and unclear. Two 
observational studies did not find any significant association between the use of aspirin and the 
development of depression.(Glaus et al., 2015; Williams et al., 2016) An open-label trial found that 
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aspirin did not provide any benefit as a treatment for a current major depressive episode and was 
associated with several side effects when added to citalopram in ten subjects with a diagnosis of major 
depressive disorder (MDD).(Ghanizadeh and Hedayati, 2014) Conversely, another interventional 
study reported that aspirin is beneficial when added to selective reuptake inhibitors (SSRI) in patients 
with MDD who had failed to respond to an antidepressant trial.(Mendlewicz et al., 2006) Considering 
that aspirin is a relatively inexpensive drug, its potential utility for the prevention of incident 
depressive symptoms could be of public health relevance.   
 
Given the aforementioned limitations in the literature, we aimed to investigate the effect of aspirin 
on the onset of depressive symptomatology in a large cohort of North American people participating 
in the Osteoarthritis Initiative.   
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METHODS 
Data source and subjects 
All participants in this study were recruited as part of the ongoing, publicly and privately funded, 
multicenter, and longitudinal Osteoarthritis Initiative (OAI) study (http://www.oai.ucsf.edu/). 
Specific datasets used were those recorded during baseline and screening evaluations (November 
2008) (V00) and those evaluating the participants until the last evaluation available (96 months; V10). 
Eligibility criteria were: i) patients at high risk of knee osteoarthritis (OA); ii) patients with 
radiological evidence of knee OA; iii) both sexes. Excluded were: i) participants having a validated 
diagnosis of rheumatoid arthritis or taking medications for this condition; ii) bilateral total knee joint 
replacement; iii) pregnancy; iv) unable to undergo a 3.0 Tesla MRI or unable to provide a blood 
sample; v) co-morbid conditions that could interfere with the study. 
The participants were recruited from four clinical sites in the US (Baltimore, MD; Pittsburgh, PA; 
Pawtucket, RI; and Columbus, OH) between February 2004 and May 2006.  All of the participants 
provided written informed consent. The OAI study protocol was approved by the institutional review 
board of the OAI Coordinating Center, University of California at San Francisco. 
 
Exposure 
The use of aspirin was assessed using a specific questionnaire investigating the name of the 
prescription medicine, duration of use, formulation code (oral, rectal, topical etc.) in the 30 days 
before the interview. Trained interviewers checked the medications used by each participant in the 
last 30 days.   
 
Outcome 
The presence of depressive symptoms was derived from the 20-item Center for Epidemiologic 
Studies-Depression (CES-D) instrument.(Radloff, 1977) The range of possible values for this scores 
is 0 to 60, where higher scores indicate more depressive symptoms.(Radloff, 1977) A cut-off of 16 
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was used for the diagnosis of depressive symptoms.(Lewinsohn et al., 1997; Veronese et al., 2016) 
The presence of depressive symptoms in the OAI was recorded at baseline and also during the 
following visits: V1 (12 months), V3 (24 months), V5 (36 months), V6 (48 months), V7 (60 months), 
V8 (72 months), V9 (84 months), and V10 (96 months).  
Covariates 
A number of variables was identified from the OAI dataset as potential confounders in the relationship 
between aspirin and incident depressive symptoms. These included: (1) physical activity evaluated 
through the Physical Activity Scale for the Elderly.(Washburn et al., 1999) This scale, validated in 
older populations, covers 12 different activities, such as walking, sports, and housework, and is scored 
from 0 to 400 and more; (2) race was defined as “white” vs. “other”; (3) smoking habits as 
“previous/current” vs. never; (4) educational level was categorized as “degree” vs. others; (5) yearly 
income as < vs. > 50,000 $ or missing data; (6) co-morbidities assessed through the modified Charlson 
comorbidity score, with higher scores indicating an increased severity of conditions(Katz et al., 
1996); (7) body mass index (BMI), as recorded by a trained nurse; and (8) the use of nonsteroidal 
anti-inflammatory drugs (NSAIDs) other than aspirin prescribed by a physician.  
 
Statistical analyses 
Descriptive analyses included means and standard deviations (SDs) for quantitative measures, and 
percentages for all discrete variables by aspirin use status at baseline. The difference in baseline 
sample characteristics by aspirin use was tested by Student’s t-tests and Chi-squared tests for 
continuous and categorical variables respectively. 
 
We ran a multivariable Cox’s regression analysis with aspirin use at baseline as the exposure and 
incident depressive symptoms at follow-up visits as the outcome. Time to event was calculated as 
time to first detection of depressive symptoms. Factors used for adjustment (age, gender, BMI, race, 
PASE score, smoking habits, education, yearly income, Charlson comorbidity index, use of NSAIDS 
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apart from aspirin, and CES-D at baseline) were those which reached a statistical significance 
between aspirin users and non-users at baseline or those significantly associated with depressive 
symptoms at follow-up (taking a p-value<0.05 as statistically significant). Furthermore, a Kaplan-
Meier survival curve was drawn to graphically display the non-adjusted cumulative incidence of 
depression by aspirin use at baseline. A log rank test was used to test the difference between aspirin 
users and non-users. 
 
In order to assess the robustness of our findings, we conducted further analyses using the propensity 
score which was estimated by using a logistic regression model regressing baseline aspirin use on the 
above-mentioned 11 baseline covariates. We also conducted 4:1 nearest-neighbor propensity score 
matching. The covariate balance for the treated and matched control groups was tested by Student’s 
t-tests and Chi-squared tests for continuous and categorical variables respectively. There were no 
significant differences in any of the baseline characteristics between the two groups (Supplementary 
Table 1). Multivariable Cox regression analysis adjusting for propensity score quintiles using the 
overall sample, and univariable Cox regression analysis using the matched controls were conducted 
to assess the association between aspirin use and incident depressive symptoms. 
 
In order to assess the influence of multicolinearity, we calculated the variance inflation factor (VIF) 
value for each independent variable. All VIFs were <2, indicating that multicolinearity was unlikely 
to be a problem in our analyses. All covariates were included in the models as categorical variables 
with the exception of age, BMI, PASE score, Charlson co-morbidity score, and CES-D points 
(continuous variables). Results of the Cox’s regression analysis were reported as hazard ratios (HRs) 
with 95% confidence intervals (CIs). The analyses were performed using SPSS 21.0 for Windows 
(SPSS Inc., Chicago, Illinois) and Stata version 14.1 (Stata Corp LP, College Station, Texas). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05. 
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RESULTS 
Study participants 
Among 4,796 potentially eligible individuals, 264 were excluded due to missing baseline CES-D 
data, and 462 were excluded for having depression (i.e. CES-D >16) at baseline. Of the remaining, 
4,070 participants, only 137 (3.6%) were using aspirin.  
 
Descriptive analyses  
The baseline characteristics by aspirin use are shown Table 1. People taking aspirin (n=137) were 
significantly older (p<0.0001), less physical active (p=0.002), richer (p=0.03), and more likely to be 
current or previous smokers (p=0.002) than those not taking aspirin (n=4,003). Conversely, no 
significant differences emerged in terms of percentage of women, BMI, race, education or use of 
other NSAIDs. As expected, people using aspirin reported a significantly higher Charlson co-
morbidity score (likely due to a higher presence of CVD and diabetes), but no differences emerged 
in terms of baseline CES-D points [aspirin users 4.6 (SD 4.0) vs. non-users 4.8 (SD 4.1), p=0.65] 
(Table 1).  
 
Association between baseline aspirin use and incident depressive symptoms 
After a median period of 8 years, 967 individuals (23.4% of baseline population) developed 
depressive symptoms. The global incidence rate of depressive symptoms was 39 events for 1000 
persons-year (95%CI=36-41). As shown in Figure 1, the incidence of depressive symptoms was 
similar in aspirin users at the baseline vs. non-users (incidence rate: 43; 95%CI=3-60 in aspirin users 
vs. 39; 95%CI=36-41 in non-users) (log-rank test p=0.63).  
 
Using a Cox’s regression analysis adjusted for eleven potential confounders, the use of aspirin was 
not associated with a significantly reduced risk of developing depressive symptoms (HR=1.12; 95% 
CI=0.78-1.62; p=0.54). Furthermore, the results of the Cox regression analysis adjusting for 
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propensity score quintiles did not appreciably change the results (HR=1.08; 95%CI=0.75-1.56; 
p=0.67). This was also the case for the analysis using propensity-score matched controls (HR=0.95; 
95%CI=0.63-1.42; p=0.79).  
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DISCUSSION 
In this study, we showed that use of aspirin is not associated with a decreased risk of incident 
depressive symptomatology over eight years of follow-up. These negative findings remained 
unaltered after adjustment for potential confounders or the use of a matched control.   
 
At baseline, no significant differences emerged for several parameters investigated, including CES-
D scores. As expected, the presence of co-morbidities was strongly associated with aspirin use which 
is likely to be due to a higher prevalence of CVD. One of the main indications for taking aspirin is 
the secondary prevention of CVD and primary prevention of CVD in high risk situations for CVD, 
particularly diabetes. Thus, the pre-existence of these conditions at baseline may have a role in 
explaining why aspirin was not effective in reducing the incidence of depressive symptoms during 
follow-up period. For example, many CVD patients would experience worsening of depression due 
to CVD itself.(Huffman et al., 2013) So apart from the CVD benefits from aspirin, this should be a 
further confounding factor that would only be partially controlled by baseline CES-D severity and 
the presence of any co-morbidity.  
 
Our findings are in general agreement with those present in the literature, in which depressive 
symptoms do not appear to benefit from aspirin use. All studies(Ghanizadeh and Hedayati, 2014; 
Glaus et al., 2015; Williams et al., 2016), except one(Mendlewicz et al., 2006), reported that the use 
of aspirin was not associated with any favorable effect on depression. In comparison with these 
previous studies, the strength of our study includes the use of propensity score matching to further 
control for background sociodemographic variables. In addition, our study had the longest follow-up 
available thus far. Since both atherosclerosis and inflammation are possible risk factors for 
depression,(Taylor et al., 2013) the use of aspirin theoretically could decrease the incidence of 
depressive symptoms. A possible reason for our null findings could be that aspirin may increase rather 
than decrease the risk of hemorrhagic small cerebrovascular lesions, which could contribute to 
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increasing the risk for vascular depression.(Almeida et al., 2010) In the Rotterdam Scan Study, for 
example, older adults who used aspirin were about three times as likely to show lobar microbleeds 
on magnetic resonance imaging compared to non-users.(Vernooij et al., 2009) Thus, it is possible that 
the beneficial effects of aspirin are counterbalanced by the higher incidence of micro-hemorrhagic 
events leading to an absence of effect. Furthermore, aspirin can increase the permeability of the gut 
barrier,(Hollander, 1999) which may drive the translocation of microbiota bacterial products, and 
thereby contribute to the pathophysiology of depression.(Slyepchenko et al., 2017) 
 
Contrary to our findings, in a large meta-analysis(Köhler et al., 2014) involving 14 trials and 6,262 
participants, the use of NSAIDs, other than aspirin, was associated with a decreased rate of depression 
and depressive symptoms. However, as stated by the authors, these data are affected by a high level 
of heterogeneity and a high risk of bias as well as a high rate of side effects.(Köhler et al., 2014) 
Among the drugs investigated, celecoxib, a COX-2 inhibitor, seems the best in decreasing depressive 
symptoms. These data are in agreement with other works suggesting that only anti-inflammatories 
inhibiting COX-2 are able to improve depression.(Na et al., 2014) The mechanism is not known, but 
one animal study showed that COX-2 inhibition can decrease the age-dependent increase of 
hippocampal inflammatory markers, and it is thus likely that in humans this may prevent not only 
depression, but also other conditions strictly associated with depression, such as anxiety and cognitive 
decline.(Casolini et al., 2002) Since aspirin is more potent in its inhibition of COX-1 than COX-
2(Rahola, 2012; Vane and Botting, 2003), it is possible that aspirin did not lead to any improvement 
in depressive symptoms for this reason. However, more research is needed, since other authors 
reported that the selective inhibition of COX-2 could also be dangerous for depression.(Maes, 2012)  
 
Another explanation of the discrepancy between elevated inflammatory markers in MDD(Kohler, 
Cristiano; Freitas, Thiago; Maes et al., 2016) and the inefficacy of aspirin administration in preventing 
depressive symptoms could be found in the difference between depressive symptoms and MDD itself, 
13 
 
or in the several subtypes of biological profiles within MDD. In particular, while depressive 
symptoms correlate with several adverse outcomes,(Maske et al., 2016) it has been observed  that 
depressive symptoms are also present in the non-clinical general population.(Nakai et al., 2015) 
Moreover, while in MDD some studies do not confirm the inflammatory theory of 
depression,(Cassano et al., 2016) others strongly suggest a sub-population that could benefit from 
treatment with anti-inflammatory drugs.(Rapaport et al., 2015) Hence, our data cannot preclude the 
possibility that aspirin is beneficial in a sub-population of individuals with MDD.(Gallagher et al., 
2016) 
 
The present findings should be considered within the limitations of the study. First, our data 
considered people who received aspirin, but we were unable to consider the impact of the dose in our 
analyses. Similarly, we had no information on whether these subjects took aspirin for the prevention 
of any CVD or as a pain-killer. Second, the diagnosis of depressive symptoms was made only using 
the CES-D. Whilst the more formal assessment of the American Psychiatric Association' Diagnostic 
and Statistical Manual [DSM] criteria) was not used, the CES-D used many symptoms defined by 
(DSM-V) for a major depressive episode and is a broadly used instrument for assessing depressive 
symptoms in population studies, presenting sensitivity and specificity of 86% and 77%, respectively, 
when compared to clinical diagnosis.(Sharp and Lipsky, 2002) Third, we did not have any 
information regarding the presence of side effects during the follow-up period, despite the fact that it 
may be important in explaining our non-significant results. Fourth, due to the limited sample size, we 
were not able to assess whether the use of aspirin was associated with a decreased risk of depressive 
symptoms in some sub-groups, e.g. people with CVD. Fifth, we had no data about the actual 
continuous aspirin use from baseline, but we assumed that subjects were taking aspirin in the context 
of a long-term treatment. Finally, we did not have information regarding use of aspirin that was 
initiated after baseline. Since this was a study with a long median follow-up of 8 years, it is possible 
that the status of the participants changed during this time-frame. Whilst is it likely that those on 
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aspirin remained on aspirin for chronic medical conditions, it is possible that some of the control 
participants started aspirin in some moment between baseline and follow-up. This is likely to have 
occurred, at least to some extent, since the participants in the OAI were chosen for having high risk 
of OA. In this case, a possible benefit of aspirin would be diluted in the analyses, and this could also 
underlie our null results.  
 
In conclusion, the use of aspirin was not associated with decreased risk of depressive symptoms 
during eight years of follow-up in a large cohort of North American people. In spite of our results 
which suggest that aspirin may not protect from incident depressive symptoms, future controlled trials 
are warranted to investigate potential benefits of this drug in individuals with MDD and higher 
baseline peripheral inflammation. 
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Table 1. Baseline characteristics according to aspirin treatment. 
 
Variable Aspirin (n=137) No aspirin (n=4003) P-valuea 
Age (years) 65.3 (8.7) 61.3 (9.2) <0.0001 
Females (%) 55.5 57.6 0.66 
BMI (kg/m2) 29.1 (4.4) 28.4 (4.7) 0.14 
White race (%) 78.1 81.9 0.26 
PASE (points) 141.7 (69.9) 163.8 (82.1) 0.002 
Smoking (previous/current) (%) 56.6 45.9 0.002 
Degree (%) 31.6 32.2 0.93 
Yearly income (<50,000 $) (%) 55.3 65.1 0.03 
Charlson co-morbidity score 0.7 (1.1) 0.4 (0.8) <0.0001 
Heart attack (%) 6.8 1.8 0.001 
Heart failure (%) 6.7 1.7 <0.0001 
Stroke (%) 8.2 2.4 0.001 
Diabetes (%) 17.6 6.8 <0.0001 
Use of NSAIDs (%) 19.7 23.9 0.31 
CES-D (points) 4.6 (4.0) 4.8 (4.1) 0.65 
 
Abbreviations: BMI Body Mass Index; PASE physical activity scale for the elderly; CES-D Center 
for Epidemiological Studies Depression. 
 
Data are mean (SD) and percentage for continuous and categorical variables respectively. 
a P-values were calculated with Student's t-tests and Chi-squared tests for continuous and 
categorical variables respectively. 
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Figure 1. Cumulative incidence of depressive symptoms by aspirin use at baseline.  
 
 
 
